19,866 Patients screened
2,001 Sites
49 Countries

Of Cerba Research clinical trials for metabolic diseases, 33% are for bowel disease and 18% are for diabetes. Furthermore, we have top-of-the-field experience with non-alcoholic steatohepatitis (NASH) and are supporting the largest Phase III NASH trial, to date.

NASH is the most severe form of non-alcoholic fatty liver disease (NAFLD). This chronic, “silent” disorder remains under-diagnosed, and its pathology, ill-defined.

Almost 12% of people in developed countries suffer from NASH. With no registered treatment and a growing number of patients developing related end-stage liver disease, we need to develop therapeutic agents urgently. At Cerba Research, we have made it our mission to support all clinical research to stop this silent killer and improve its diagnosis and treatment.

Supporting the largest Phase III NASH study ever conducted


patients randomized


samples received and analyzed, so far

Clinical support solutions for your NASH research

The current gold standard for NASH diagnosis is liver biopsy. At Cerba Research, we routinely process, stain, and interpret these specimens by collaborating with a network of liver pathologists all over the world. In addition, we test for other liver biomarkers and provide non-invasive fibrosis scoring.

  • Markers of genetic predisposition
    • PNPLA3
    • TM6FS2
    • miRNA such as miR21 and miR122
  • Liver biopsies
  • Liver inflammation biomarkers
    • CK18 M30 & M65
    • Adiponectin
    • FGF-19 and FGF-21
    • Hyaluronic acid, PIIINP and TIMP-1
  • Metabolomics
  • Glycemic and lipid biomarkers
    • sdLDL
    • HbA1c
    • Apolipoprotein A2, C3 and E
  • Non-invasive scores for fibrosis
    • FIB-4 index, ELF, FibroTest (FibroSure), SteatoTest, MELD score, etc.